Loading
A phase 3 trial testing Givinostat in myeloproliferative neoplasms, now recruiting.
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera is a phase 3 interventional study registered as NCT06093672, led by Italfarmaco with PPD Development, LP, and recruiting on the registry. Official title: Randomised, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL. Planned enrolment is 220 participants (estimated). The study started in 2024-03-26 and primary completion is expected in 2026-07. No results have been posted on ClinicalTrials.gov.
Shares Italfarmaco, Givinostat, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis).